Table 4.
Other studies
| Author, year | No. of patients | Tumor size (mm) | Dose (Gy)/fx | BED (Gy) | 2-yr LC (%) | 2-yr OS (%) |
|---|---|---|---|---|---|---|
| Kwon et al. [8], 2010 | 42 | 2.5 (1.4–4.3) | 33/ 3 | 69.3 | 3-yr: 67.5 | 3-yr: 58.6 |
| Andolino et al. [9], 2011 | 60 | 3.1 (1.0–6.5) | 44/3 (60) | 108.9 (60) | 90 | 67 |
| 40/5 (40) | 72 (40) | |||||
| Kang et al. [10], 2012 | 47 | 2.9 (1.3–7.8) | 57/ 3 | 165.3 | 94.6 | 68.7 |
| Bujold et al. [11], 2013 | 102 | 7.2 (1.4–23.1) | 36/ 6 | 57.6 | 1-yr: 87 | Median: 17 mo |
| Yoon et al. [12], 2013 | 93 | 2.0 (1.0–6.0) | 45/ 3 | 112.5 | 3-yr: 92.1 | 3-yr: 53.8 |
| Scorsetti et al. [13], 2015 | 43 | 4.8 (1–12.5) | 48–75/3 (48) | 124.8–262.5 (48) | 64.4 | 45.3 |
| 36–60/6 (52) | 57.6–120 (52) | |||||
| Huertas et al. [14], 2015 | 77 | 2.4 (0.7–6.3) | 45/ 3 | 112.5 | 99 | 56.6 |
| Kimura et al. [15], 2015 | 65 | 1.6 (0.5–5.4) | 48/ 4 | 105.6 | 100 | 76.0 |
| Takeda et al. [16], 2016 | 90 | 2.3 (1.0–4.0) | 35/5 (11) | 59.5 (11) | 3-yr: 96.3 | 3-yr: 66.7 |
| 40/5 (89) | 72.0 (89) | |||||
| Current study | 44 | 1.4 (0.8–5.2) | 45/3 (23) | 112.5 (23) | 3-yr: 95 | 3-yr: 80.7 |
| 60/3 (77) | 180 (77) |
Values are presented as median (range) or number (%).
BED, biologically equivalent dose; LC, local control; OS, overall survival; RTOG, Radiation Therapy Oncology Group; CTCAE, Common Terminology Criteria for Adverse Events; CPS, Child-Pugh score; ALBI, albumin-bilirubin.